Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.60 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320686 | 0.90 | ESR2 (0.50) | ESR2NR1H2ABCB1NAMPTMAPK1 | |
| SCHEMBL322595 | 0.84 | S1PR5 (0.64) | ESR2NR1H2MAPK1S1PR1S1PR5 | |
| SCHEMBL321185 | 0.83 | S1PR1 (0.64) | ESR2NR1H2ABCB1S1PR1S1PR5 | |
| SCHEMBL322179 | 0.80 | S1PR5 (0.52) | ESR2ABCB1S1PR1S1PR5MAPT | |
| SCHEMBL15164308 | 0.79 | ESR2 (0.50) | ESR2NR1H2S1PR1S1PR5MAPT | |
| SCHEMBL321077 | 0.78 | S1PR5 (0.54) | ESR2ABCB1S1PR1S1PR5S1PR3 | |
| SCHEMBL17552126 | 0.76 | ESR2 (0.52) | ESR2NR1H2NAMPTMAPK1MAPT | |
| SCHEMBL1014594 | 0.76 | MAPT (0.59) | ESR2NR1H2NAMPTMAPK1MAPT | |
| SCHEMBL29590844 | 0.75 | ESR2 (1.00) | ESR2NR1H2NAMPTMAPK1DDB1 | |
| SCHEMBL450677 | 0.75 | ESR2 (1.00) | ESR2NR1H2NAMPTMAPK1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48301-E1 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2020-11-10 | — | — | US | disclosed |
| EP-2590980-B1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2017-09-20 | — | — | EP | disclosed |
| EP-2590980-B1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2017-09-20 | — | — | EP | disclosed |
| US-9670220-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2017-06-06 | — | — | US | disclosed |
| US-9670220-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2017-06-06 | — | — | US | disclosed |
| US-20150284403-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-10-08 | — | — | US | disclosed |
| US-20150284403-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-10-08 | — | — | US | disclosed |
| US-9096612-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| US-9096612-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| US-8796262-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2014-08-05 | — | — | US | disclosed |
| US-8796262-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2014-08-05 | — | — | US | disclosed |
| US-20140066433-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE INC (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066433-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE INC (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130203737-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-08-08 | — | — | US | disclosed |
| US-20130203737-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-08-08 | — | — | US | disclosed |
| EP-2590980-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004373-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066433-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | S1PR5, S1PR1, S1PR3 | ESR2 1256/4885NR1H2 80/4885ABCB1 3164/4885 |
| US-20130203737-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | ESR2 1060/4885NR1H2 79/4885ABCB1 1875/4885 |
| US-20150284403-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | S1PR5, S1PR1, S1PR3 | ESR2 1256/4885NR1H2 80/4885ABCB1 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.